Regained CG01 rights and secured a new license with Spark, discontinued CGT2, and advanced the COZY pain program. Net sales and cash declined year-over-year, with a continued focus on partnering and portfolio expansion.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.